# PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia

> **NCT05313165** · NA · RECRUITING · sponsor: **LimFlow, Inc.** · enrollment: 100 (estimated)

## Conditions studied

- Critical Limb Ischemia
- Chronic Limb-Threatening Ischemia
- Peripheral Arterial Disease

## Interventions

- **DEVICE:** LimFlow Stent Graft System

## Key facts

- **NCT ID:** NCT05313165
- **Lead sponsor:** LimFlow, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-22
- **Primary completion:** 2027-05-01
- **Final completion:** 2027-05-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05313165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05313165, "PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05313165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*